Pre Eliminary Study : Pengaruh Pemberian First Line Drug Antituberculosis Terhadap Jumlah Hydropic Swelling Pada Sel Hepar Tikus Putih Jantan (Rattus Novergicus Strain Wistar) Yang Diinduksi Selama dua Minggu”.
DOI:
https://doi.org/10.22219/sm.Vol15.SMUMM1.8484Keywords:
hydropic swelling, First Line Drug, Antituberculosis.Abstract
Konsumsi First Line Drug Antituberculosis menyebabkan gangguan hati diakibatkan oleh stress oksidatif, sehingga dapat menyebabkan kerusakan hati yang dapat dilihat pada peningkatan jumlah hydropic swelling pada sel hepar tikus. Penelitian ini adalah penelitian pendahuluan dengan memberikan First Line Drug Antituberculosis selama dua minggu. Untuk mengetahui pengaruh First Line Drug Antituberculosis terhadap jumlah hydropic swelling sel hati pada tikus putih jantan yang diinduksi selama dua minggu. Penelitian ini menggunakan metode penelitian True experimental dengan post test only control group design. menggunakan 10 tikus dalam 2 kelompok, kontrol positif (diinduksi First Line Drug Antituberculosis), kontrol negatif (tidak diinduksi obat). Hasil penelitian ini menunjukkan adanya perbedaan yang bermakna pada perlakuan antara K- dan K+ dengan meggunakan uji t tidak berpasangan, dengan hasil signifikansi t- test (p<0,05). Kesimpulan yang didapatkan ada pengaruh pemberian First Line Drug Antituberculosis (pirazinamid, etambutol, Isoniazid, Rifampicin) terhadap jumlah hydropic swelling pada sel hati tikus putih jantan (Rattus Novergicus Strain Wistar) yang diinduksi selama dua minggu.
Downloads
References
Boyer TD, Manns MP & Sanyal AJ, 2012. Zakim and Boyer's HEPATOLOGY A Text Book of Liver Disease. 6th ed. Philadelphia: Elsevier saunders [online],tersedia dari: https://www.sciencedirect.com/ science/book/ 9781437708813.
Chou H, Lin S, Chen W, Ke W, Chao P, Hsiao F. Monitoring liver function among patients who initiated anti-tuberculosis drugs in Taiwan, 2000–2011. Int J Tuberc Lung Dis. 2014;18:1245–51.View ArticlePubMedGoogle Scholar
Devarbhavi H. Antituberculosis drug-induced liver injury: current perspective. Trop Gastroenterol. 2011;32:167–74.
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:S231–79.
Garg PK, Tandon RK. Antituberculosis treatment induced hepatotoxicity (in) Sharma SK, Mohan A, editors Tuberculosis. 1st ed. New Delhi : Jaypee:2001:p-500-06.
Guyton AC & Hall JE, 2016, Text Book of Medical Physiologi, 13th ed, Elsevier, USA.
Heifets LB. Antimicrobial agents: Pyrazinamide. In: Yu VL, Merigan TC,Barriere SL. eds. Anti-microbial therapy and vaccines. Baltimore: Williams & Wilkins, 1999:668-676.
Himawan, S. 1992. Patologi. Jakarta: Penerbit Buku Kedokteran EGC. hlm. 86.
Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. Hepatology 2002;35:883-889
Isoniazid. In: Kucers A, Crowe SM, Grayson ML, et al. The use of antibiotics, 5th ed. Boston: Butterworth-Heineman, 1997;1179-1210.
Kasno, P. A. 2008. Patologi Hati dan Saluran Empedu Ekstra Hepatik. Semarang: Balai Penerbit Universitas Diponegoro
Katzung, Bertram. 2013.Farmakologi dasar dan klinik. 10th ed. Jakarta : EGC. pp. 1171-1193.
Laurence DR and Bacharach AL. 1964. Evaluation of Drug Activities: Pharmacometrics. Academic Press. London and New York. pp: 135-79.
Loho IM, Hasan I, 2014, Drug-Induced Liver Injury - Tantangan dalam Diagnosis, CDK-214/ Vol. 41 ,No. 3, Jakarta , IDI [online], http://www.kalbemed.com/Portals/6/04_214CME_Drug Induced%20 Liver%20Injury%E2%80%93Tantangan%20dalam%20Diagnosis.pdf
Maria Adriana Rangel, Isabel Pinto Pais, Raquel Duarte, Isabel Carvalho 2017. Case Report Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges. Volume 2017, Article ID 5741896, 4 pages https://doi.org/10.1155/2017/5741896.
Niruri dan I Made, 2006. Buku Ajar Toksikologi Umum. Bali: Univetsitas Udayana.
Ohno M, Yamaguchi I, Yamamoto I, et al. Slow Nacetyltransferase 2 genotype affects the incidence of Isoniazid and Rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000;4:256-261.
Pilheu JA, DeSalvo MC, Koch O. Liver alterations in antituberculosis regimens containing Pyrazinamide. Chest 1981;80:720-724.
Rojko, JL dan Hall WC ,1996. New Issues and Methodelogies in Hepatic Injury and Repair, Pubmed, Vol 24, pp. 4-12, [online], https://www.ncbi.nlm.nih.gov/pubmed/8839276
Rom WN & Garay SM. Tuberculosis Philadelphia : Lippincott Williams & Wilkins, 2004.
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–52.View ArticlePubMedGoogle Scholar
Saukkonen, D. L. Cohn, R. M. Jasmer et al., “An official ATS statement: hepatotoxicity of antituberculosis therapy,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 8, pp. 935–952, 2006.
Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, et al. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis. 2014;18:347–51.View ArticlePubMedGoogle Scholar
Steele MA, Des Prez RM. The role of Pyrazinamide in tuberculosis chemotherapy. Chest 1988;94:842-844.
Teleman MD, Chee CBE, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis. 2002;6:699–705.PubMedGoogle Scholar
Tost JR, Vidal R, Caylà J, Díaz-Cabanela D, Jiménez A, Broquetas JM, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9:534–40.
Tostmann A, Boeree MJ, Aarnoutse RE, de Lange W, Van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192–202.
Tostmann, M. J. Boeree, R. E. Aarnoutse, W. C. M. de Lange, A. J. A. M. van der Ven, and R. Dekhuijzen, “Antituberculosis drug-induced hepatotoxicity: concise up-to-date review,” Journal of Gastroenterology and Hepatology, vol. 23, no. 2, pp. 192– 202, 2008
WHO, 2017, Global Tuberculosis Profile, s.l, WHO [online], http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf?sequence=1.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7.View ArticlePubMedGoogle Scholar
Zierski MB, Bek E. Side effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. Tubercle 1980;61:41-49.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
